ST Pharm Co.Ltd Asset Resilience Ratio
ST Pharm Co.Ltd asset resilience ratio. ST Pharm Co.Ltd (237690) has an Asset Resilience Ratio of 7.72% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of ST Pharm Co.Ltd to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of ST Pharm Co.Ltd (2016–2025)
Asset resilience ratio of ST Pharm Co.Ltd from 2016 to 2025. This chart shows how ST Pharm Co.Ltd's Asset Resilience Ratio has changed over time. Read ST Pharm Co.Ltd (237690) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down ST Pharm Co.Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see ST Pharm Co.Ltd balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩60.44 Billion | 7.72% |
| Total Liquid Assets | ₩60.44 Billion | 7.72% |
Asset Resilience Insights
- Limited Liquidity: ST Pharm Co.Ltd maintains only 7.72% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
ST Pharm Co.Ltd Industry Peers by Asset Resilience Ratio
Compare ST Pharm Co.Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
GeneBioTech Co. Ltd
KQ:086060 |
Pharmaceuticals | 22.68% |
|
Sam Chun Dang Pharm. Co. Ltd
KQ:000250 |
Pharmaceuticals | 6.87% |
|
NatureCell Co.Ltd
KQ:007390 |
Pharmaceuticals | 0.00% |
|
Oscotec Inc
KQ:039200 |
Pharmaceuticals | 66.73% |
|
Komipharm International Co. Ltd
KQ:041960 |
Pharmaceuticals | 0.00% |
|
Mezzion Pharma Co.Ltd
KQ:140410 |
Pharmaceuticals | 0.00% |
|
Aprogen Healthcare & Games Inc
KQ:109960 |
Pharmaceuticals | 6.55% |
|
Caregen Co.Ltd
KQ:214370 |
Pharmaceuticals | 4.58% |
ST Pharm Co.Ltd Asset Resilience Ratio by Year (2016–2025)
ST Pharm Co.Ltd asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for ST Pharm Co.Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 7.72% | ₩60.44 Billion ≈ $40.96 Million |
₩782.57 Billion ≈ $530.33 Million |
-0.24pp |
| 2024-12-31 | 7.97% | ₩57.52 Billion ≈ $38.98 Million |
₩721.88 Billion ≈ $489.20 Million |
+2.05pp |
| 2023-12-31 | 5.92% | ₩40.00 Billion ≈ $27.11 Million |
₩675.44 Billion ≈ $457.73 Million |
+5.92pp |
| 2022-12-31 | 0.00% | ₩10.00 ≈ $0.01 |
₩570.65 Billion ≈ $386.72 Million |
-13.21pp |
| 2021-12-31 | 13.21% | ₩65.87 Billion ≈ $44.64 Million |
₩498.57 Billion ≈ $337.87 Million |
-11.64pp |
| 2020-12-31 | 24.85% | ₩110.72 Billion ≈ $75.03 Million |
₩445.57 Billion ≈ $301.96 Million |
+13.64pp |
| 2019-12-31 | 11.21% | ₩38.24 Billion ≈ $25.92 Million |
₩341.08 Billion ≈ $231.15 Million |
-19.96pp |
| 2018-12-31 | 31.17% | ₩107.71 Billion ≈ $72.99 Million |
₩345.51 Billion ≈ $234.14 Million |
-3.50pp |
| 2017-12-31 | 34.68% | ₩132.30 Billion ≈ $89.66 Million |
₩381.50 Billion ≈ $258.54 Million |
+3.36pp |
| 2016-12-31 | 31.32% | ₩115.20 Billion ≈ $78.07 Million |
₩367.78 Billion ≈ $249.24 Million |
-- |
About ST Pharm Co.Ltd
ST Pharm Co. Ltd., a contract development manufacturing organization, provides products for pharmaceutical and non-pharmaceutical area in South Korea. The company offers chemistry manufacturing control (CMC) services, which includes analytical method development; in-house reference standard testing; analytical method qualification/validation; analytical characterization; and CMC documentation. It… Read more